Vivos Therapeutics, Inc.(VVOS)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Vivos Therapeutics, Inc. (VVOS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VVOS at 27.8/100 on a 32-signal composite quality model, placing it at rank #2,574 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Vivos Therapeutics, Inc. reports quarterly revenue of $5.2M, net income of $-5.5M, an operating margin of -93.6%. Top institutional holders of VVOS by reported 13-F value include GEODE CAPITAL MANAGEMENT, IHT Wealth Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. VVOS trades on the Nasdaq exchange and files with the SEC under CIK 1716166. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VVOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vivos Therapeutics, Inc. directly from SEC EDGAR.
AI Quality Score
27.8/100
AI Rank
#2,574
Revenue
$5.2M
Net Income
$-5.5M
Free Cash Flow
$-3.6M
Operating Margin
-93.6%
VVOS key financials by period
Vivos Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$17.4M
$-21.2M
-114.1%
FY 2024
10-K
$15.0M
$-11.1M
-74.3%
FY 2023
10-K
$13.8M
$-13.6M
-125.3%
FY 2022
10-K/A
$16.0M
$-23.8M
-156.2%
FY 2021
10-K
$16.9M
$-20.3M
-120.7%
FY 2020
10-K
$13.1M
$-12.1M
-92.2%
Institutions holding VVOS
Institutional investors reporting a position in Vivos Therapeutics, Inc. on SEC Form 13F.
